CRB-701 Shows Robust Phase 1/2 Oncology Data; FDA Aligns on Registrational Study Designs
CRBP sits 53% above its 52-week low of $6.72 on elevated volume (2.1× avg).
Summary
Corbus Pharmaceuticals announced strong Phase 1/2 clinical data for its lead oncology drug, CRB-701, in oropharyngeal and cervical cancers, along with FDA alignment on registrational study designs.
Key Events · Product Development and Regulatory · CRBP
-
Robust Phase 1/2 Data for CRB-701
Updated clinical data from the Phase 1/2 study of CRB-701 showed a 42.9% confirmed objective response rate (cORR) in 2L oropharyngeal squamous cell carcinoma (OPSCC) and 34.4% cORR in 2L cervical cancer at the 3.6 mg/kg dose, with a manageable safety profile.
-
FDA Alignment on Registrational Studies
The company achieved broad alignment with the FDA on the design of registrational studies for CRB-701 in both 2L OPSCC and 2L cervical cancer, with the OPSCC study ("TEMPO-1") expected to begin in summer 2026.
-
Upcoming ASCO Presentation
The detailed clinical findings will be presented at the 2026 American Society for Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, with an oral presentation on May 29 and a poster on May 30.
Analysis · CRBP · Life Sciences
This filing provides highly positive clinical data for Corbus's lead oncology asset, CRB-701, demonstrating robust efficacy and a favorable safety profile in two difficult-to-treat cancers. The confirmed alignment with the FDA on registrational study designs for both oropharyngeal squamous cell carcinoma and cervical cancer significantly de-risks the development pathway, providing a clear route to potential market approval. This progress is critical for a clinical-stage biotech, potentially enhancing its valuation and future financing prospects, especially given recent reports of increased cash burn.
At the time of this filing, CRBP was trading at $10.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.3M. The 52-week trading range was $6.72 to $20.56. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.